Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib versus imatinib in newly diagnosed chronic phase Philadelphia chromosome-positive chronic myeloid leukemia
NL-OMON31003Phase 3Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2007
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of dasatinib and imatinib, sponsored by Bristol Myers Squibb. Planned start Nov 2007; status: not yet recruiting.
02
Drugs
dasatinibimatinib
Beyond the preview
Go deeper on NL-OMON31003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31003.